Benzinga - by Avi Kapoor, Benzinga Staff Writer.
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
Bristol-Myers Squibb Company (NASDAQ: BMY)
- Dividend Yield: 4.81%
- B of A Securities analyst Geoff Meacham downgraded the stock from Buy to Neutral and cut the price target from $68 to $60 on Jan. 3, 2024. This analyst has an accuracy rate of 62%.
- Deutsche Bank analyst James Shin initiated coverage on the stock with a Hold rating and a price target of $55 on Nov. 9, 2023. This analyst has an accuracy rate of 72%.
- Recent News: Bristol Myers Squibb released the first disclosure of data from the Phase 3 CheckMate -67T trial of the subcutaneous formulation of Opdivo (nivolumab) compared to intravenous (IV) Opdivo in advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy.
- Dividend Yield: 6.53%
- Piper Sandler analyst David Amsellem maintained an Overweight rating and lowered the price target from $32 to $22 on Nov. 22, 2023. This analyst has an accuracy rate of 71%.
- Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and slashed the price target from $27 to $22 on Oct. 11, 2023. This analyst has an accuracy rate of 68%.
- Recent News: Organon recently announced the availability of XACIATO 2% by prescription.
- Dividend Yield: 3.62%
- Mizuho analyst Ann Hynes maintained a Buy rating and cut the price target from $88 to $86 on Nov. 2, 2023. This analyst has an accuracy rate of 74%.
- Morgan Stanley analyst Erin Wright maintained an Overweight rating on the stock and cut the price target from $110 to $100 on Nov. 2, 2023. This analyst has an accuracy rate of 76%.
- Recent News: CVS Health is reportedly looking to close some of its pharmacies located within Target stores in the coming months.
Read More: Alphabet, Microsoft And 3 Stocks To Watch Heading Into Tuesday
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.